Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Related Citations for PubMed (Select 24200972)

1.

Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib.

De Luca A, D'Alessio A, Gallo M, Maiello MR, Bode AM, Normanno N.

Cell Cycle. 2014;13(1):148-56. doi: 10.4161/cc.26899. Epub 2013 Oct 29.

2.

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.

3.

Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.

Ma C, Niu X, Luo J, Shao Z, Shen K.

Cancer Sci. 2010 Oct;101(10):2220-6. doi: 10.1111/j.1349-7006.2010.01662.x. Epub 2010 Aug 5.

PMID:
20701607
4.

Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.

Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, González-Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC, Arteaga CL.

Oncogene. 2011 Oct 6;30(40):4163-74. doi: 10.1038/onc.2011.130. Epub 2011 Apr 18.

5.

Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.

Vazquez-Martin A, Oliveras-Ferraros C, Colomer R, Brunet J, Menendez JA.

Ann Oncol. 2008 Jun;19(6):1097-109. doi: 10.1093/annonc/mdm589. Epub 2008 Feb 17.

6.

Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.

Brady SW, Zhang J, Seok D, Wang H, Yu D.

Mol Cancer Ther. 2014 Jan;13(1):60-70. doi: 10.1158/1535-7163.MCT-13-0518. Epub 2013 Nov 18.

7.

Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.

Normanno N, Campiglio M, Maiello MR, De Luca A, Mancino M, Gallo M, D'Alessio A, Menard S.

Breast Cancer Res Treat. 2008 Nov;112(1):25-33. Epub 2007 Nov 30.

PMID:
18060492
8.
9.

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.

Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7795-800. Epub 2006 May 8.

10.

Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.

D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N.

Breast Cancer Res Treat. 2010 Sep;123(2):387-96. doi: 10.1007/s10549-009-0649-x. Epub 2009 Nov 28.

PMID:
19946741
11.

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.

McDermott MS, Browne BC, Conlon NT, O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O'Donovan N.

Mol Cancer. 2014 Jun 24;13:157. doi: 10.1186/1476-4598-13-157.

12.

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.

Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R.

Breast Cancer Res. 2011 Aug 31;13(4):R84. doi: 10.1186/bcr2936.

13.

Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.

Nam HJ, Im SA, Oh DY, Elvin P, Kim HP, Yoon YK, Min A, Song SH, Han SW, Kim TY, Bang YJ.

Mol Cancer Ther. 2013 Jan;12(1):16-26. doi: 10.1158/1535-7163.MCT-12-0109. Epub 2012 Nov 9.

14.

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.

Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL.

Clin Cancer Res. 2013 Oct 1;19(19):5390-401. doi: 10.1158/1078-0432.CCR-13-1038. Epub 2013 Aug 15.

15.

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.

Breast Cancer Res. 2007;9(4):R50.

16.

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.

Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9.

PMID:
21153051
17.

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.

Jegg AM, Ward TM, Iorns E, Hoe N, Zhou J, Liu X, Singh S, Landgraf R, Pegram MD.

Breast Cancer Res Treat. 2012 Dec;136(3):683-92. doi: 10.1007/s10549-012-2252-9. Epub 2012 Oct 23.

PMID:
23089982
18.

Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.

Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus SS, Mao Y, He J, Wulfkuhle JD, Petricoin EF 3rd, Osada T, Yang XY, Hartman ZC, Clay TM, Blackwell KL, Lyerly HK, Spector NL.

Mol Cancer Ther. 2011 Aug;10(8):1367-74. doi: 10.1158/1535-7163.MCT-10-0991. Epub 2011 Jun 14.

19.

Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.

Zhu X, Wu L, Qiao H, Han T, Chen S, Liu X, Jiang R, Wei Y, Feng D, Zhang Y, Ma Y, Zhang S, Zhang J.

J Cell Biochem. 2013 Dec;114(12):2643-53. doi: 10.1002/jcb.24611.

PMID:
23794518
20.

Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.

Sengupta S, Schiff R, Katzenellenbogen BS.

Breast Cancer Res Treat. 2009 Sep;117(2):243-51. doi: 10.1007/s10549-008-0186-z. Epub 2008 Sep 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk